FDA approves Ivosidenib for Myelodysplastic Syndromes caused by mutations in IDH1.

Published Date: 28 Oct 2023

A small study that showed 38.9% of patients with relapsed or refractory disease entering complete remission served as the basis for the FDA's approval.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer mortality continuing to decline, says report

2.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

3.

Financial hardship common in patients with cancer

4.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

5.

Advancing Health in Africa


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot